Incretin effects on β-cell function, replication, and mass: the human perspective.
about
Potential Bioactive Compounds from Seaweed for Diabetes ManagementDulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetesConcise review: pancreas regeneration: recent advances and perspectivesPractical combination therapy based on pathophysiology of type 2 diabetesIndolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study.Human β-cell regeneration: progress, hurdles, and controversy.The potential role of incretin therapy in the hospital setting.Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives.Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic conditionComparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesmiR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker developmentThe role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetesCoadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaTreatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.Longer-Term Physiological and Metabolic Effects of Gastric Bypass SurgeryManaging diabetes from first diagnosis: choosing well-tolerated therapies with durability.Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care.Making β cells from adult cells within the pancreas.At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspectiveLixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.Sleeve gastrectomy, but not duodenojejunostomy, preserves total beta-cell mass in Goto-Kakizaki rats evaluated by three-dimensional optical projection tomography.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.Anti-diabetic potential of selected Malaysian seaweedsLinagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
P2860
Q26797339-7BBC6EA0-C8D4-4FF1-BA33-5ED2B79B724AQ26861768-712321DD-F70A-441B-98CD-B123DDBE838AQ27013646-59AB2DE5-9E2D-46DB-815C-E6B1A6DA22E6Q28076530-25827A9F-F30E-4495-88C0-11539C1B02ECQ33551724-5E5F1751-DE47-4E6D-89DD-2721FBCDB8F4Q33776142-4D65FB97-F198-4739-91C5-7D116AD06AF6Q33792390-DD101A18-DC6E-440B-9A8C-7BB342F075C6Q33844872-7CA02406-4380-44EF-8C55-84CFD1016FBBQ34344032-73A20B66-CA04-4D93-855A-A3529E2E04BAQ34498840-5E1E468E-0529-437E-8347-F2AB3FC9F00AQ34592864-6A382508-B5B5-4921-81EA-05CD1262F2ADQ35184904-68BBF3F9-54CF-4660-9762-5F10B2C360A4Q35305506-3B1BA07B-E06A-45D2-836D-DFAC6B13ACA2Q35994230-3AE65CAA-0EDF-4700-A767-8DA807EFC173Q36072493-1FAF2F77-AFD2-49C4-BAF0-9203209464C8Q36109279-B343E8AC-246F-4A9F-99B5-999EDA44EEB3Q36182540-64E50405-A5A8-4180-8F89-E8C0D14507BFQ36567296-130B370F-4387-490C-B837-8D37CFFE19C0Q36720596-811CD15E-EA02-413D-AE34-2DABAC038B8BQ36833164-576FF9F9-ACA8-4C23-8328-6A68F9600A36Q37550281-7F71894C-8BEE-4A9D-A97E-2B446C9AD841Q38020015-3ED4EDAD-DB97-420E-8843-444CAD11AA5BQ38068629-C3828A9E-0428-4A06-9195-51889A689B32Q38127356-AF635EDD-DA63-49C2-85EE-CED95CFFAB86Q38200704-82C5B5C1-0D9A-4DC4-87F9-3CA68F1D54FFQ38285665-06E0E312-8052-4B5B-87B9-6A0CB6D55CD0Q38901991-6C7CDB07-BDE9-4538-9ED4-B23054B95FA4Q38931845-A82262DD-EB52-4A61-B4C2-43804B334E80Q39101720-9289DEBA-737D-49AF-8F83-7F5D3A8D210DQ39345729-F16779DB-59BB-458C-A8C2-0D2293AE9C1AQ40998901-EF783EC2-E987-49A5-A53F-0060B9106EBDQ42463784-9C5809FB-93E6-49BD-8BA3-FCD9D03FF4A7Q42665424-B09FDB37-B8B1-498B-AA0E-4C711CC88584Q51301524-99C6342B-A55F-45F0-9A3F-1F435F8D3BFEQ51301791-B28A6E8C-A673-4807-888E-595129BE30F7Q54580077-B71DC022-FB1F-491B-86A0-F719F16FFDD9Q56940876-46B160BE-F4F8-4017-A7CD-C75FF999B771Q57591345-E33CD7A3-8424-4D14-AE67-9BA7CDC4284B
P2860
Incretin effects on β-cell function, replication, and mass: the human perspective.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Incretin effects on β-cell function, replication, and mass: the human perspective.
@en
Incretin effects on β-cell function, replication, and mass: the human perspective.
@nl
type
label
Incretin effects on β-cell function, replication, and mass: the human perspective.
@en
Incretin effects on β-cell function, replication, and mass: the human perspective.
@nl
prefLabel
Incretin effects on β-cell function, replication, and mass: the human perspective.
@en
Incretin effects on β-cell function, replication, and mass: the human perspective.
@nl
P2860
P356
P1433
P1476
Incretin effects on β-cell function, replication, and mass: the human perspective.
@en
P2093
Alan J Garber
P2860
P304
P356
10.2337/DC11-S230
P407
P478
34 Suppl 2
P577
2011-05-01T00:00:00Z